Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Biogen Plunges After Making Changes to Alzheimer's Drug Trial | BioSpace
Biogen (@biogen) / Twitter
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Company | Biogen
Biogen Stock Flies On Upgrade; Why Alzheimer's Is A $7 Billion Opportunity | Investor's Business Daily
Home | Biogen
Biogen - Биоген - Biogen - Биоген updated their cover photo.
Biogen shakes up R&D role, splitting it into two
Biogen Foundation | Biogen
Home | Biogen
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug | Barron's
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache | Fierce Pharma
Broad scales up as Biogen scales back in Kendall Square - The Boston Globe
Home | Biogen
Biogen - Биоген - Photos | Facebook
Biogen Foundation | Biogen
Biogen - Биоген - Photos | Facebook
Under-pressure Biogen aims to please restive investors with bigger, better board | Fierce Pharma
Biogen and Ionis join in $1 billion neuroscience pact
Home | Biogen
Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst | Fierce Pharma
Biogen's stock rises 3% after releasing new data on late-stage Alzheimer's drug
